2024
Global patterns of rebound to normal RSV dynamics following COVID-19 suppression
Thindwa D, Li K, Cooper-Wootton D, Zheng Z, Pitzer V, Weinberger D. Global patterns of rebound to normal RSV dynamics following COVID-19 suppression. BMC Infectious Diseases 2024, 24: 635. PMID: 38918718, PMCID: PMC11201371, DOI: 10.1186/s12879-024-09509-4.Peer-Reviewed Original ResearchEstimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study
Hartner A, Li X, Echeverria-Londono S, Roth J, Abbas K, Auzenbergs M, de Villiers M, Ferrari M, Fraser K, Fu H, Hallett T, Hinsley W, Jit M, Karachaliou A, Moore S, Nayagam S, Papadopoulos T, Perkins T, Portnoy A, Minh Q, Vynnycky E, Winter A, Burrows H, Chen C, Clapham H, Deshpande A, Hauryski S, Huber J, Jean K, Kim C, Kim J, Koh J, Lopman B, Pitzer V, Tam Y, Lambach P, Sim S, Woodruff K, Ferguson N, Trotter C, Gaythorpe K. Estimating the health effects of COVID-19-related immunisation disruptions in 112 countries during 2020–30: a modelling study. The Lancet Global Health 2024, 12: e563-e571. PMID: 38485425, PMCID: PMC10951961, DOI: 10.1016/s2214-109x(23)00603-4.Peer-Reviewed Original ResearchConceptsCatch-up activitiesVaccine-preventable disease burdenCatch-upVaccine Impact Modelling ConsortiumImmunisation servicesMiddle-income countriesEffectiveness of HPV vaccinationVaccine effectivenessAffected cohortBill & Melinda Gates FoundationImmunisation coverageLow-incomeLong-term effectsWHO-UNICEFDisease burdenVaccination coverageCalendar yearImmunisation effortsMelinda Gates FoundationMitigation measuresCountriesYears of vaccinationYellow fever vaccine
2023
Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study
Löwensteyn Y, Zheng Z, Rave N, Bannier M, Billard M, Casalegno J, Pitzer V, Wildenbeest J, Weinberger D, Bont L, Putten M, Smit-Kleinlugtenbeld E, Peetsold M, van der Kuip M, van Goudoever H, van Keulen B, Boot A, Kloos R, van Gool S, Snepvangers Y, Kuijpers A, Menelik N, de Crom S, Miedema C, Tusscher G, van Giessen J, de Moor R, Faber M, Breukels M, Jaddoe V, Duijts L, Lutterman C, Vink I, Tramper-Stranders G, Oudshoorn A, Ritman A, Dubbink-Verheij G, Bolt J, Cakir C, Rietveld E, Bekhof J, Rings E, de Swart J, Driessen G, Doedens R, Nijssen L, van Onzenoort-Bokken L, Meijneke R, van Scherpenzeel M, Faber T, de Groof F, Schouten S, van de Zande J, de Coul M, Henriet S, Stol K, van Rossem M, Jacobs M, van Houten M, Zuurbier R, Plötz F, de Vries A, van der Heide R, van Boekholt A, de Jong G, Rashid A, Roelofs M, Illy K, Reijmerink N, van Dorth S, Schipper S, Rosias P, Teirlinck A. Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study. The Journal Of Infectious Diseases 2023, 228: 1394-1399. PMID: 37477906, PMCID: PMC10640768, DOI: 10.1093/infdis/jiad282.Peer-Reviewed Original ResearchChanges in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited StatesPlanning for Mpox on a College Campus: A Model-Based Decision-Support Tool.
Savinkina A, Chitwood M, Kwon J, Pitzer V, Gonsalves G, Paltiel A. Planning for Mpox on a College Campus: A Model-Based Decision-Support Tool. Annals Of Internal Medicine 2023, 176: 340-347. PMID: 36716454, PMCID: PMC10338074, DOI: 10.7326/m22-2734.Peer-Reviewed Original ResearchConceptsSustained transmissionNational InstituteLow-risk groupHigh-risk populationPopulation of MSMHealth-National InstituteResidential college campusSymptomatic casesHypothetical cohortCongregate settingsStudy populationPreemptive vaccinationReactive vaccinationInfectious diseasesVaccinationDrug abuseBasic reproductive numberFuture outbreaksFrequent physical contactMSMReproductive numberOutbreakDaysMenTimely detection
2022
Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel
Prunas O, Weinberger D, Pitzer V, Gazit S, Patalon T. Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel. Clinical Infectious Diseases 2022, 76: 113-118. PMID: 36484301, PMCID: PMC10202431, DOI: 10.1093/cid/ciac315.Peer-Reviewed Original ResearchConceptsMaccabi Healthcare ServicesBNT162b2 vaccineSecond doseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionPositive polymerase chain reaction testSARS-CoV-2 infectionPfizer BNT162b2 vaccineCoronavirus 2 infectionVaccine-induced immunityVaccine-induced protectionPolymerase chain reaction testIncidence of infectionCoronavirus disease 2019COVID-19Chain reaction testShort-term effectivenessCase-control designLong-term effectivenessVaccine effectivenessSymptomatic infectionLong-term protectionDisease 2019Delta variant